Combination treatment for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two treatments for advanced liver cancer (hepatocellular carcinoma): a bile acid supplement called tauroursodeoxycholic acid plus an immunotherapy drug (a PD-1/PD-L1 inhibitor) that helps your immune system fight the cancer. The goal is to see if this combination is safe and effective in people who have not yet had any whole-body cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of a type of liver cancer called hepatocellular carcinoma (HCC).
- Your cancer must be advanced, meaning it cannot be removed with surgery, and you must not have had any prior whole-body cancer treatment.
- You need to be at least 18 years old.
- You must have at least one tumor that can be measured on a scan.
- Your liver, kidneys, and blood counts must be within acceptable limits (the study team will check this).
- You must not have had certain serious liver complications, like severe cirrhosis, liver failure, or a previous liver transplant, and you should not have active gallbladder disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial tests a combination of two treatments for advanced liver cancer that cannot be removed by surgery. One treatment delivers chemotherapy directly to the tumor, and the other uses tiny beads to block the tumor's blood supply. This approach may help shrink tumors and slow the cancer's growth.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
This study tests a new combination treatment for liver cancer that cannot be removed by surgery. It combines a procedure called TACE (which delivers chemotherapy directly to the tumor) with an investigational drug, ivonescimab, which helps the immune system fight cancer. The goal is to see if this combination is safe and effective for people whose cancer has not spread beyond the liver.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.